Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsTaha Merghoub, Jedd D. Wolchok, Daniel Hirschhorn, Cailian Liu
Life of this patent
Estimating the term…
Abstract
The presently disclosed subject matter provides methods and compositions for treating cancer (e.g., melanoma). It relates to chimeric antigen receptors (CARs) that specifically target MDA (e.g., Trp1), and immunoresponsive cells comprising such CARs. The presently disclosed MDA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
Claims25
-59. (canceled)
A method of reducing tumor burden in a subject and/or increasing or lengthening survival of a subject having neoplasia, comprising administering to the subject an effective amount of an immunoresponsive cell comprising an extracellular antigen-binding domain, a transmembrane domain, and an intracellular domain,
- wherein the extracellular antigen-binding comprises a heavy chain variable region (VH) comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 1, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 2, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 3;
- and a light chain variable region (VL) comprising a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
- 4, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
- 5, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
- 6,
- thereby inducing tumor cell death in the subject and/or increasing or lengthening survival of the subject.
-63. (canceled)
(canceled)
-73. (canceled)
-85. (canceled)
Dependencies are inferred from the claim text.